BL-7010
| Indication: | Celiac Disease | |
| Mode of Action: | Gliadin Sequestering | |
| Stage of development: | Pre-clinical | |
| Patent status: | Patents pending worldwide, 20 years expiration in 2026 |
BL-7010 Overview
BL-7010 is a novel, non-absorbable, high molecular weight polymer intended for the treatment of celiac disease. It has a high affinity for gliadins, the immunogenic peptides present in gluten that cause celiac disease. BL-7010 is chemically stable at a wide pH range, not biodegradable and is water soluble. It works by acting locally in the gastrointestinal tract, binding and neutralizing gliadins and then undergoing excretion
Pre-Clinical Data
In vitro BL-7010 has been shown to specifically bind gliadins and to prevent toxic damage to the epithelial tissue. Experiments in vivo in a murine model of celiac disease have shown that BL-7010 prevents pathological damage to the small intestine, helps to preserve the integrity of the intestinal mucosa and reduces inflammation. In addition it has been shown to have no effect on weight gain and to have no other toxic effects. Additional studies showed that BL-7010 is specific to gliadins, the immunogenic peptides present in gluten that cause celiac disease, and does not interact with non-related enzymes or vitamins in the digestive tract. These results imply that BL-7010 will not affect the absorbance of vitamins or the digestion process and therefore will not lead to malnutrition.
BL-7010 was invented by Prof. Jean-Christophe Leroux.
BL-7010 is being developed by BioLineRx Ltd. under a worldwide exclusive license agreement with Univalor.
